• About Us
    • Our Team
  • Science
  • Pipeline
  • News & Events
  • Contact
  • Menu Menu

Closing the gap in eyecare

Developing novel, orally administered ophthalmology drugs to meet the needs of millions of patients at risk of vision loss.

Learn More

Science

Addressing the large unmet medical need to develop more effective and less burdensome therapies for patients and their caregivers.

Learn More

Pipeline

Developing danegaptide, an orally administered, small molecule drug with a novel mode of action.

Developing orally administered P2X7 receptor antagonists with anti-inflammatory and neuroprotective properties.

Learn More

Latest News

  • Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy 24 June 2025
  • Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy 25 January 2024
  • Privacy Policy
LinkedIn

Breye Therapeutics ApS
Agern Allè 24
2970 Hørsholm
Denmark

CVR: 40279865

  • About Us
    • Our Team
  • Science
  • Pipeline
  • News & Events
  • Contact
Our Sustainable Framework
© Copyright - Breye Therapeutics ApS
  • Privacy Policy
Scroll to top Scroll to top Scroll to top